Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLU-263 in advanced systemic mastocytosis as monotherapy or with azacitidine
NL-OMON53678Phase 2Not yet recruiting
- Sponsor
- Blueprint Medicines
- Start
- May 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of elenestinib and azacitidine in systemic mastocytosis (SM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), Aggressive Systemic Mastocytosis (ASM) and 2 more (2 arms), sponsored by Blueprint Medicines. Planned start May 2023; status: not yet recruiting.
02
Drugs
elenestinibazacitidine
03
Conditions
systemic mastocytosis (SM)systemic mastocytosis with associated hematological neoplasm (SM-AHN)Aggressive Systemic Mastocytosis (ASM)mast cell leukemia (MCL)hematopoietic malignancies
Beyond the preview
Go deeper on NL-OMON53678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53678.